Our Partners


Shire's business continues to advance medical science to develop new and better life-saving products and therapies for patients.

Shire is a leading developer of clotting factors to treat hemophilia. This includes recombinant and plasma-based factor VIII – the clotting protein missing from the blood of people with hemophilia A – and therapies for people that develop inhibitors against clotting factor. Shire also has a number of research and development programs aimed at improving the treatment of hemophilia and other bleeding disorders. - Shire